George Jean 4
4 · Cyteir Therapeutics, Inc. · Filed Jun 24, 2021
Insider Transaction Report
Form 4
George Jean
Director
Transactions
- Conversion
Series B Convertible Preferred Stock
2021-06-22−7,500,000→ 0 total(indirect: See Footnote)→ Common Stock (2,200,187 underlying) - Conversion
Series C Convertible Preferred Stock
2021-06-22−832,026→ 0 total(indirect: See Footnote)→ Common Stock (244,081 underlying) - Conversion
Common Stock
2021-06-22+2,444,268→ 2,444,268 total(indirect: See Footnote)
Footnotes (2)
- [F1]Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date.
- [F2]Shares held by Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. The Reporting Person is a managing director of LSV Associates II, LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein.